Search

Displaying results 3811 - 3820 of 7604 in total
  1. Drug

    Influenza A virus A/Switzerland/9715293/2013 (H3N2) live (attenuated) antigen

    go.drugbank.com/drugs/DB11035
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.

  2. Drug

    Influenza B virus B/Brisbane/60/2008 live (attenuated) antigen

    go.drugbank.com/drugs/DB11037
    ApprovedInvestigationalWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.

  3. Drug

    Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB11040
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.

  4. Drug

    Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB11041
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.

  5. Drug

    Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB11042
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.

  6. Drug

    Influenza B virus B/Massachusetts/2/2012 BX-51B antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB11046
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.

  7. Drug

    Stem-cell derived exosome vesicle products

    go.drugbank.com/drugs/DB15743
    Experimental

    Once secreted into extracellular fluid, exosomes are taken up by their target cells or carried to distant target sites. … Various bioactive molecules (including lipids, proteins, mRNAs, and tRNAs) are used to enrich exosomes.

  8. Drug

    Alicaforsen

    go.drugbank.com/drugs/DB06224
    Investigational

  9. Drug

    Urofollitropin

    go.drugbank.com/drugs/DB00094
    ApprovedVet approvedWithdrawn

    It consists of two non-covalently linked, non-identical glycoproteins designated as the alpha- and beta- subunits. The alpha- and beta- subunits have 92 and 111 amino acids. … Urofollitropin may also be used to cause the ovary to produce several follicles, which can then be harvested for use in gamete intrafallopian transfer (GIFT) or in vitro fertilization (IVF).

  10. Drug

    BB 21217

    go.drugbank.com/drugs/DB17373
    Investigational

    BB 21217 is an anti-BCMA CAR T cell therapy that uses the same CAR molecule as [idecabtagene vicleucel] (bb2121), but adds the PI3K inhibitor bb007 during ex vivo culture to enrich the drug product (DP